iffering approaches for the treatment of coronary bifurcation and ostial lesions (CBOL) continue to feed the debate over which stent designs and stenting techniques are most effective.


According to the Centers for Disease Control and Prevention, more than 70 million Americans currently live with cardiovascular disease, with 700,000 dying from it each year.
In an age where heart disease is responsible for 29 percent of all U.S. deaths, cutting-edge technology and know-how is crucial to today’s cath labs.

Just when drug-eluting stents (DES) were going to revolutionize interventional cardiology, new reports that DES may be associated with increased risk of late-stent thrombosis have many physicians putting the brakes on DES use. Despite this significant bump in the road, stent manufacturers are forging ahead with clinical trials on novel systems and on plans to roll out new DES platforms in 2008.

September 6, 2007 — ProSolv CardioVascular, a FUJIFILM company (ProSolv), announced at the 12th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) that it has further enhanced its CardioVascular Image and Information Systems (CVIIS) product line with the integration of Corridor4DM (previously known as 4DM-SPECT) capabilities, allowing clinicians to access 4DM review, analysis and quantification tools from any ProSolv CardioVascular workstation.

September 10, 2007 - Four analyses of three-year follow-up data that were presented at the ESC Congress 2007 showed that the CYPHER Sirolimus-eluting Coronary Stent may be considered an appropriate alternative to bypass surgery in patients with blockages in two or more coronary arteries (multivessel disease).

September 10, 2007 - Signalife launched the sales of its new, FDA-approved, ambulatory 12-lead ECG cardiovascular monitor.
In private meetings throughout the United States over the next 10 days, the company's cardiovascular experts and Signalife's technology team will present the technologies to the several hospitals, facilities and physician-groups.
"We will be visiting more than a dozen hospitals with thousands of beds and hundreds of physicians, beginning now, in cities nationwide," said Lowell Harmison, CEO of Signalife.

September 7, 2007 - Gary Ansel, M.D., Riverside Methodist Hospital, successfully implanted the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface, a stent graft designed to open blockages in the superficial femoral artery in the thigh, which is used to treat a common form of peripheral arterial disease (PAD).

Combining all features of the ACIST CMS and Voyager systems onto one platform, the ACIST CVi Contrast Delivery System for cardiovascular angiographic procedures enhances the ease
of contrast and saline injection for physicians, nurses and technicians.
The ACIST CVi Contrast Delivery System serves as one injection system for all cardiac and vascular angiography procedures. Its fourth-generation technology re-
portedly provides ease of use for staff, while obtaining images with less contrast used.

Possis Medical Inc. will feature the newest advancements in its “Complete Solution for Thrombus,” including the AngioJet Ultra Thrombectomy System, AngioJet Spiroflex and Spiroflex VG catheters and its Fetch Aspiration Catheter.

Sony Electronics recently introduced its LMD-2450MD 24-inch monitor, which offers 10-bit signal processing and Sony ChromaTRU color balance technology for ultra high performance.
The LMD-2450MD displays a 1920 by 1080P full HD signal, enabling the purest reproduction of images captured by today’s HD surgical cameras.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now